Merck, U211050-2G, DMT-2′O-TBDMS-rU Phosphoramidite

General description
RNA phosphoramidites, along with RNA CPG, and analogous to DNA synthesis support the synthesis of sequence-specific RNA oligonucleotides for RNA interference (RNAi) and can be used in target validation and other drug development techniques.Modern phosphoramidite-mediated synthesis has enabled routine high-yielding preparations of RNA oligonucleotides. High-quality RNA phosphoramidites are key to low failure rates, the high biological activity of synthesis products, and cost-effectiveness.Key Features:

Industry-standard 2′O-TBDMS protective group
Consistent lot-to-lot purity and performance
Compatible with deprotection methods based on methylamine or AMA
Standard RNA phosphoramidites provide excellent coupling results whenused with ETT or BTT as an activator; best results are obtained withActivator 42
Capping with standard acetic anhydride capping reagent rather than withFast Deprotection Cap A
Manufactured under a certified ISO 9001 quality systemDMT-2′O-TBDMS-rU Phosphoramidite is configured for ABI™ Synthesizers.

Other Notes
RNA monomers feature hydroxyl groups at the 2′-position. In order toprevent the formation of unnatural 2′-5′ phosphordiester bonds duringchain elongation, the 2′OH group is protected with a trialkyl-silyl group, tertbutyldimethylsilyl (TBDMS). The TBDMS group is stable under the acidicconditions used to remove the DMT group during the synthesis cycle, butcan be removed by a variety of methods after cleavage and deprotection ofthe RNA oligomer, e.g., with a solution of tetrabutylammonium fluoride(TBAF) in tetrahydrofurane (THF) or with triethylamine hydrofluoride.
Legal Information
ABI is a trademark of Applera Corporation or its subsidiaries in the US and/or certain other countries
OligoPilot is a registered trademark of Cytiva
ÄKTA is a registered trademark of Cytiva